UnitedHealthcare initially denied coverage for Novartis’ drug Zolgensma, a one-time treatment for spinal muscular atrophy, but has since approved coverage for all six requests it received for the new drug.
The advanced gene treatment was approved by the FDA in May for most children under age 2 with spinal muscular atrophy. Insurers have been reluctant to cover new gene treatments based on medical necessity.
UnitedHealth Group’s CMO, Richard Migliori, MD, told The Washington Post the coverage reversals were based on clinical evidence, not on public attention generated by the denials.
Read more here.
More articles on payers:
UnitedHealth records $3.3B profit in Q2
Minnesota hospitals ask state to investigate BCBS over new policy ending coverage for 7 forms of routine care
New York insurer opens office in hospital
At the Becker's 5th Annual Fall Payer Issues Roundtable, taking place November 2–3 in Chicago, payer executives and healthcare leaders will come together to discuss value-based care, regulatory changes, cost management strategies and innovations shaping the future of payer-provider collaboration. Apply for complimentary registration now.
